Search results for "interquartile range"

showing 10 items of 263 documents

2018

Background Due to the high prevalence of depressive disorders, it is mandatory to develop therapeutic strategies that provide universal access and require limited financial and human resources. Web-based therapeutic approaches fulfill these conditions. Objective The objective of our study was to assess the feasibility, acceptability, and efficacy of a supervised, individualized 8-week Web-based exercise intervention conducted for patients with moderate to severe depression. Methods We recruited 20 patients with unipolar depression and randomly assigned them into 2 groups (intervention, exercise program group, n=14, and control, treatment-as-usual group, n=6). At baseline, depressive sympto…

medicine.medical_specialtyStrength trainingbusiness.industry030227 psychiatryTest (assessment)law.invention03 medical and health sciencesPsychiatry and Mental health0302 clinical medicineQuality of lifeRandomized controlled trialInterquartile rangelawEndurance trainingIntervention (counseling)Physical therapymedicinebusiness030217 neurology & neurosurgeryDepression (differential diagnoses)JMIR Mental Health
researchProduct

Right ventricular function and iron deficiency in acute heart failure

2021

Abstract Aims Iron deficiency (ID) is a frequent finding in patients with chronic and acute heart failure (AHF) along the full spectrum of left ventricular ejection fraction (LVEF). Iron deficiency has been related to ventricular systolic dysfunction, but its role in right ventricular function has not been evaluated. We sought to evaluate whether ID identifies patients with greater right ventricular dysfunction in the setting of AHF. Methods and results We prospectively included 903 patients admitted with AHF. Right systolic function was evaluated by tricuspid annular plane systolic excursion (TAPSE) and the ratio TAPSE/pulmonary artery systolic pressure (TAPSE/PASP). Iron deficiency was de…

medicine.medical_specialtyVentricular Dysfunction Right030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineVentricular Function Left03 medical and health sciences0302 clinical medicineLeft ventricle ejection fraction[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInterquartile rangeInternal medicinemedicineHumans030212 general & internal medicineSystoleAgedAged 80 and overHeart FailureIron deficiency.Ejection fractionAnemia Iron-DeficiencybiologyTransferrin saturationbusiness.industryIron deficiencyRight ventricle ejection fractionStroke VolumeGeneral MedicineMiddle AgedPrognosismedicine.disease[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemTricuspid annular plane systolic excursionFerritinBlood pressureHeart failureVentricular Function Rightbiology.proteinCardiologyFemaleCardiology and Cardiovascular MedicineHeart failure with preserved ejection fractionbusiness
researchProduct

Right Heart Dysfunction and Readmission Risk Across Left Ventricular Ejection Fraction Status in Patients With Acute Heart Failure.

2021

BACKGROUND: Right heart dysfunction (RHD) parameters are increasingly important in heart failure (HF). This study aimed to evaluate the association of advanced RHD with the risk of recurrent admissions across the spectrum of left ventricular ejection fraction (LVEF). METHODS AND RESULTS: We included 3383 consecutive patients discharged for acute HF. Of them, in 1435 patients (42.4%), the pulmonary artery systolic pressure could not be measured accurately, leaving a final sample size of 1948 patients. Advanced RHD was defined as the combination of a ratio of tricuspid annular plane systolic excursion/pulmonary artery systolic pressure of less than 0.36 and significant tricuspid regurgitation…

medicine.medical_specialtyVentricular Dysfunction RightHeart failureRegurgitation (circulation)Patient ReadmissionVentricular Function LeftreadmissionsVentricular Dysfunction LeftInterquartile rangemedicine.arteryInternal medicinemedicineHumansHeart FailureEjection fractionbusiness.industryStroke Volumeleft ventricular ejection fractionmedicine.diseasePrognosisBlood pressureSample size determinationHeart failurePulmonary arteryRight heartCardiologyVentricular Function RightCardiology and Cardiovascular Medicinebusinessright heart dysfunction
researchProduct

Central Obesity and Survival in Subjects With Coronary Artery Disease

2011

Objectives The aim of this study was to examine the association of central (waist circumference [WC] and waist-hip ratio [WHR]) and total obesity (body mass index [BMI]) measures with mortality in coronary artery disease (CAD) patients. Background The question of which measure of obesity better predicts survival in patients with CAD is controversial. Methods We searched OVID/Medline, EMBASE, CENTRAL, and Web of Science from 1980 to 2008 and asked experts in the field for unpublished data meeting inclusion criteria, in which all subjects had: 1) CAD at baseline; 2) measures of WC or WHR; 3) mortality data; and 4) a minimum follow-up of 6 months. Results From 2,188 studies found, 6 met inclus…

medicine.medical_specialtyWaistbusiness.industryHazard ratioConfidence intervalSurgeryWaist–hip ratioInterquartile rangeInternal medicineCohortMedicinebusinessCardiology and Cardiovascular MedicineBody mass indexCohort studyJournal of the American College of Cardiology
researchProduct

Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma

2019

In patients with uncontrolled, severe eosinophilic asthma treatment with anti-IL-5(-receptor) (anti-IL5(R)) antibodies is a promising therapeutic approach. Results of clinical trials demonstrate a very good effectiveness and safety profile of these drugs. However, there is limited data on real-life effectiveness because the drugs have been approved for just a few years. Aim of the present study was to evaluate the real-life effectiveness of the anti-IL5(R) antibodies mepolizumab, reslizumab and benralizumab in severe eosinophilic asthma shortly after approval in Germany. In 119 patients (n=44 male, mean age 54±14 yrs., BMI 27.5±6.2, FEV1 1.9±0.8L (64±21%), 5±3 exacerbations in the last 12 m…

medicine.medical_specialtybiologybusiness.industryEosinophilic asthmaBenralizumabClinical trialTherapeutic approachchemistry.chemical_compoundReslizumabchemistryInterquartile rangeInternal medicinebiology.proteinmedicineAntibodybusinessMepolizumabmedicine.drugAirway pharmacology and treatment
researchProduct

Compassionate Use of the PASCAL Transcatheter Valve Repair System for Severe Tricuspid Regurgitation

2019

Abstract Objectives The purpose of this observational first-in-human experience was to investigate the feasibility and safety of the PASCAL transcatheter valve repair system and its impact on short-term clinical outcomes in patients with severe tricuspid regurgitation (TR). Background Transcatheter repair of severe TR is a promising treatment option for patients at prohibitive surgical risk. Large leaflet coaptation gaps and tethering represent common features that challenge the application of transcatheter repair techniques. Methods Twenty-eight patients with severe TR were treated with the PASCAL system in a compassionate use experience at 6 sites. All patients had heart failure due to se…

medicine.medical_specialtybusiness.industryCompassionate UsePascal (programming language)First in human030204 cardiovascular system & hematologymedicine.diseaseSurgery03 medical and health sciences0302 clinical medicineInterquartile rangeHeart failureEtiologymedicineObservational study030212 general & internal medicineCardiology and Cardiovascular MedicinebusinessProspective cohort studycomputercomputer.programming_languageJACC: Cardiovascular Interventions
researchProduct

Prognostic Parameters For Remission Of and Survival In Acquired Hemophilia A: Results Of The GTH-AH 01/2010 Multicenter Study

2013

Abstract Acquired hemophilia A (AHA) is a rare autoimmune disorder caused by neutralizing autoantibodies against coagulation factor VIII (FVIII:C). Immunosuppressive treatment may result in remission of disease over a period of days to months. Until remission, patients are at high risk of bleeding and complications from immunosuppression. Prognostic parameters to predict remission and the time needed to achieve remission could be helpful to guide treatment intensity, but have not been established so far. GTH-AH01/2010 was a prospective multicenter cohort study using a standardized immunosuppressive treatment protocol. The primary study endpoint was time to achieve partial remission (PR, def…

medicine.medical_specialtybusiness.industryImmunologyComplete remissionCell BiologyHematologyOff-label useBiochemistryHemophiliasInterquartile rangeInternal medicineImmunologyAcquired hemophiliamedicineHemotherapyRituximabbusinessCohort studymedicine.drugBlood
researchProduct

Serum Heat Shock Protein 60 in Acute Heart Failure: A New Biomarker?

2012

Heat shock protein 60 (HSP60) is a mitochondrial protein constitutively expressed in the majority of cells, and its expression is up-regulated by a variety of stressors. In heart failure, HSP60 is released from cardiomyocytes. The authors speculate that increased serum HSP60 (sHSP60) may be related to the severity of heart failure. This investigation sought to assess the association between sHSP60 and the composite end point of death ⁄ readmission in patients with acute heart failure (AHF). A total of 132 consecutive patients were admitted for AHF. The independent association between sHSP60 and the end point was assessed with Cox regression. During a median follow-up of 7 months (interquart…

medicine.medical_specialtybusiness.industryProportional hazards modelIncidence (epidemiology)Hazard ratioEmergency Nursingmedicine.diseaseConfidence intervalSurgeryInterquartile rangeHeat shock proteinInternal medicineHeart failureEmergency MedicineCardiologymedicineBiomarker (medicine)Cardiology and Cardiovascular MedicinebusinessCongestive Heart Failure
researchProduct

Anastomotic Techniques and Associated Morbidity in Total Minimally Invasive Transthoracic Esophagectomy

2019

Objective: The aim of this study was to describe anastomotic techniques used for total minimally invasive transthoracic esophagectomy (ttMIE) and to analyze the associated morbidity. Background: ttMIE faces increasing application in surgical treatment of esophageal cancer. For esophagogastric reconstruction, different anastomotic techniques are currently used, but their effect on postoperative anastomotic leakage and morbidity has not been investigated. Patients and Methods: Patients were selected from a basic dataset, collected during a 5-year period from 13 international surgical high-volume centers. Endpoints were anastomotic leakage rate and postoperative morbidity in correlation to ana…

medicine.medical_specialtybusiness.industryRetrospective cohort studyTransthoracic esophagectomyEsophageal cancerAnastomosismedicine.disease3. Good healthSurgery03 medical and health sciences0302 clinical medicineAnastomotic leakageInterquartile range030220 oncology & carcinogenesismedicine030211 gastroenterology & hepatologySurgeryComplicationbusinessSurvival analysisAnnals of Surgery
researchProduct

Prior Treatment with Alemtuzumab Interferes with T-Cell Engraftment After Allogeneic Stem Cell Transplantation in Patients with Chronic Lymphocytic L…

2009

Abstract Abstract 3351 Poster Board III-239 Objectives: The majority of patients with chronic lymphocytic leukemia (CLL) who receive allogeneic hematopoietic cell transplantation (HCT) have fludarabine-refractory disease. The most active single agent in this disease stage is alemtuzumab. Alemtuzumab has a long half-life and induces profound T-cell depletion (TCD). Since TCD may mitigate graft-versus leukemia effects we evaluated „pre-conditioning“ with alemtuzumab followed by a washout period in order to minimize in vivo T-cell depletion of the graft in a phase II study (NCT 00337519). Methods: Patients received cytoreductive treatment with 3 × 30 mg alemtuzumab weekly prior to HCT. The sch…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentChronic lymphocytic leukemiaImmunologyCell BiologyHematologyHematopoietic stem cell transplantationmedicine.diseaseBiochemistryGastroenterologySurgeryFludarabineTransplantationInterquartile rangeInternal medicinemedicineAlemtuzumabbusinessProgressive diseaseBusulfanmedicine.drugBlood
researchProduct